Article

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple Myeloma

2020-12-15

Abstract excerpt

<h4>Background: </h4> Multiple myeloma (MM) patients may undergo relapse and experience resistance to existing therapies. Cereblon (CRBN) is key mediator of the bioactivities of immunomodulatory drugs (IMiDs), including lenalidomide. Moreover, genetic alteration of CRBN is frequently detected in IMiD-resistant patients and considered to contribute to IMiD resistance. Thus, overcoming resistance to drugs, including...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fb04b332-baa2-589c-bbda-e548b515739f
DOI: 10.21203/rs.3.rs-125312/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple MyelomaDOI 10.21203/rs.3.rs-125312/v1Read

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Semantic proximity Read

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent mannerSemantic proximity Read

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read

Cereblon enhancer methylation and IMiD resistance in multiple myelomaSemantic proximity Read

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read